WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 408128
CAS#: 579515-63-2
Description: GW806742X is a potent MLKL inhibitor, also a human and murine necroptosis inhibitor. GW806742X binds the MLKL pseudokinase domain with a Kd value of 9.3 μM and has anti-necroptosis activity. GW806742X has activity against VEGFR2. GW806742X blocked necroptosis and IL-33 release in vitro and reduced eosinophilia in Aspergillus fumigatus extract-induced asthma in vivo, an allergic inflammation model that is highly dependent on IL-33.
MedKoo Cat#: 408128
Name: GW806742X
CAS#: 579515-63-2
Chemical Formula: C25H22F3N7O4S
Exact Mass: 573.1406
Molecular Weight: 573.5512
Elemental Analysis: C, 52.35; H, 3.87; F, 9.94; N, 17.10; O, 11.16; S, 5.59
Synonym: GW806742X; GW-806742X; GW 806742X;
IUPAC/Chemical Name: 3-(4-(Methyl(4-(3-(4-(trifluoromethoxy)phenyl)ureido)phenyl)amino)pyrimidin-2-ylamino)benzenesulfonamide
InChi Key: SNRUTMWCDZHKKM-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H22F3N7O4S/c1-35(22-13-14-30-23(34-22)31-18-3-2-4-21(15-18)40(29,37)38)19-9-5-16(6-10-19)32-24(36)33-17-7-11-20(12-8-17)39-25(26,27)28/h2-15H,1H3,(H2,29,37,38)(H,30,31,34)(H2,32,33,36)
SMILES Code: O=S(C1=CC=CC(NC2=NC=CC(N(C)C3=CC=C(NC(NC4=CC=C(OC(F)(F)F)C=C4)=O)C=C3)=N2)=C1)(N)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X has activity against VEGFR2 (IC50=2 nM). |
| In vitro activity: | Firstly, it was proved that non-selective AURKA and AURKB inhibitors GW809897X and GW806742X treatment reduced cell proliferation of leukemia cell line (K-562) with a potency constant IC50 of > 5 µM and 1.47 µM, respectively. Reference: Sci Rep. 2020 Dec 4;10(1):21272. https://pubmed.ncbi.nlm.nih.gov/33277547/ |
| In vivo activity: | In addition, airway inflammation and lung eosinophil infiltration were reduced asthmatic mice in response to GW80 (GW806742X) treatment (Fig. 6H–K). In summary, the ability of the necroptotic inhibitor GW80 to attenuate pathology in an IL-33-dependent Asp.-induced asthma model suggests a role for necroptosis in IL-33 release in asthma. Reference: FEBS J. 2019 Feb;286(3):507-522. https://pubmed.ncbi.nlm.nih.gov/30576068/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 100.0 | 174.35 |
The following data is based on the product molecular weight 573.5512 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Moreira-Nunes CA, Mesquita FP, Portilho AJS, Mello Júnior FAR, Maués JHDS, Pantoja LDC, Wanderley AV, Khayat AS, Zuercher WJ, Montenegro RC, de Moraes-Filho MO, de Moraes MEA. Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia. Sci Rep. 2020 Dec 4;10(1):21272. doi: 10.1038/s41598-020-78024-8. PMID: 33277547; PMCID: PMC7718893. 2. Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Engler M, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS J. 2019 Feb;286(3):507-522. doi: 10.1111/febs.14738. Epub 2019 Jan 4. PMID: 30576068. |
| In vitro protocol: | 1. Moreira-Nunes CA, Mesquita FP, Portilho AJS, Mello Júnior FAR, Maués JHDS, Pantoja LDC, Wanderley AV, Khayat AS, Zuercher WJ, Montenegro RC, de Moraes-Filho MO, de Moraes MEA. Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia. Sci Rep. 2020 Dec 4;10(1):21272. doi: 10.1038/s41598-020-78024-8. PMID: 33277547; PMCID: PMC7718893. |
| In vivo protocol: | 1. Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Engler M, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS J. 2019 Feb;286(3):507-522. doi: 10.1111/febs.14738. Epub 2019 Jan 4. PMID: 30576068. |
1: Moreira-Nunes CA, Mesquita FP, Portilho AJS, Mello Júnior FAR, Maués JHDS, Pantoja LDC, Wanderley AV, Khayat AS, Zuercher WJ, Montenegro RC, de Moraes- Filho MO, de Moraes MEA. Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia. Sci Rep. 2020 Dec 4;10(1):21272. doi: 10.1038/s41598-020-78024-8. PMID: 33277547; PMCID: PMC7718893.
2: Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Engler M, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS J. 2019 Feb;286(3):507-522. doi: 10.1111/febs.14738. Epub 2019 Jan 4. PMID: 30576068.
3: Lusthaus M, Mazkereth N, Donin N, Fishelson Z. Receptor-Interacting Protein Kinases 1 and 3, and Mixed Lineage Kinase Domain-Like Protein Are Activated by Sublytic Complement and Participate in Complement-Dependent Cytotoxicity. Front Immunol. 2018 Feb 23;9:306. doi: 10.3389/fimmu.2018.00306. PMID: 29527209; PMCID: PMC5829068.
4: González-Juarbe N, Gilley RP, Hinojosa CA, Bradley KM, Kamei A, Gao G, Dube PH, Bergman MA, Orihuela CJ. Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia. PLoS Pathog. 2015 Dec 11;11(12):e1005337. doi: 10.1371/journal.ppat.1005337. PMID: 26659062; PMCID: PMC4676650.
